Jamil Khurram 4

What Happened

• Jamil Khurram, Chief Medical Officer of Galectin Therapeutics (GALT), exercised options to acquire 568 shares on 2026-05-26 at an exercise price of $1.23 per share (cost ~$699), and those 568 shares were sold in the open market the same day for total proceeds reported as $1,761 (weighted average sale price reported as $3.10).
• The filing also shows a derivative disposition entry for 568 shares at $0.00, which reflects the conversion/cancellation of the derivative instrument upon exercise. The transactions were executed pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-05-26; exercise price: $1.23; reported sale proceeds: $1,761.
• Reported weighted average sale price: $3.10; footnote states individual sale prices ranged $3.00–$3.01 and the filer can provide a full breakdown on request (Footnote F2).
• Transactions were made under a Rule 10b5-1 plan adopted Feb 2, 2026 and disclosed in the issuer’s 10-Q filed May 15, 2026 (Footnote F1).
• Vesting schedule for the related options noted in the filing: 16,250 shares vesting on each of June 30, 2025; Dec 31, 2025; June 30, 2026; and Dec 31, 2026 (Footnote F3).
• Shares owned after the transaction are not specified in this Form 4.
• Filing date: 2026-05-28 (timely — Form 4 filed within the required reporting window).

Context

• This was effectively an exercise-and-sell (same-day sale) transaction: the insider exercised stock options and sold the resulting shares, a common way to cover exercise costs or diversify. Such sales are often routine and do not necessarily signal a change in the insider’s view of the company.
• The $0.00 derivative disposition line represents the cancellation/conversion of the option instrument upon exercise, not additional cash proceeds.